Infinity Pharmaceuticals, Inc. INFI incurred a loss of 20 cents per share in the third quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 18 cents. Moreover, the figure came against the year-ago reported earnings of 23 cents.
Also, the company’s recognized royalty revenues of $0.34 million lagged the Zacks Consensus Estimate of $1 million. Meanwhile, the company did not record any revenues in the year-ago quarter.
Shares of Infinity have lost 11.1% year to date versus the industry’s increase of 3.1%.
Quarter in Detail
Research and development expenses escalated 31.5% year over year to $7.1 million in the reported quarter, mainly due to an increase in clinical and development activities for IPI-549.
General and administrative expenses rose 5.9% to $3.6 million in the reported quarter.
As of Sep 30, 2019, Infinity had total cash and cash equivalents of $52 million compared with $63 million at the end of Jun 30, 2019. The company expects its existing cash, cash equivalents and available-for-sale securities to be adequate for meeting its capital needs at least through the next 12 months.
Pipeline Update
In September 2019, the company initiated a phase II, MARIO-3 study in collaboration with Roche AG RHHBY evaluating IPI-549 in combination with Tecentriq and Abraxane (nab-paclitaxel) for the treatment of front-line triple negative breast cancer (TNBC). The above-mentioned study also includes a cohort evaluating IPI-549 in combination with Tecentriq and Avastin (bevacizumab) for front-line PDL1+ and PDL1- renal cell cancer (RCC) patients. Infinity plans to present data from the study in 2020.
The company is also conducting a phase I/Ib MARIO-1 study evaluating IPI-549 as a monotherapy and in combination with Bristol Myers’ BMY PD-1 immune checkpoint inhibitor Opdivo for addressing patients with advanced solid tumors. Infinity plans to complete enrollment by this year-end and present the study data next year.
Infinity is also conducting a phase II MARIO-275 study investigating the combo of IPI-549 plus Opdivo in platinum-refractory, I/O naïve patients with advanced urothelial cancer.
Meanwhile, in September 2019, Arcus Biosciences RCUS initiated a phase I study in collaboration with Infinity evaluating IPI-549 in combination with AB298, Arcus' dual adenosine receptor antagonist, and Doxil, a chemotherapy, for treating patients with advanced triple negative breast cancer (TNBC).
2019 Outlook
The company expects net loss for 2019 in the range of $40-$50 million, unchanged from the previous quarter’s guidance.
Infinity Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Infinity Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Infinity Pharmaceuticals, Inc. Quote
Zacks Rank
Infinity currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment